Harvard Bioscience
HBIO
60 hedge funds and large institutions have $7.29M invested in Harvard Bioscience in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 29 reducing their positions, and 14 closing their positions.
5.45% less ownership
Funds ownership: 42.79% → 37.34% (-5.4%)
13% less funds holding
Funds holding: 69 → 60 (-9)
13% less capital invested
Capital invested by funds: $8.39M → $7.29M (-$1.1M)
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
69% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AE
AMH Equity
Great Neck,
New York
|
+$256K |
| 2 |
Two Sigma Investments
New York
|
+$131K |
| 3 |
Two Sigma Advisers
New York
|
+$93.1K |
| 4 |
WN
Williams & Novak
Westlake Village,
California
|
+$80.1K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$48.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$426K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$370K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$299K |
| 4 |
BlackRock
New York
|
-$234K |
| 5 |
Goldman Sachs
New York
|
-$92.5K |
HBIO Hedge Fund Activity: Q3 2025 in Review
60 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q3 2025, worth a combined $7.29M — down 13% from $8.39M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of HBIO and 5 opened new positions — a net loss of 9 holders — while 29 trimmed existing stakes and 9 added.
The largest buyer was AMH Equity, adding an estimated $256K. The largest seller was Granahan Investment Management, cutting an estimated $426K.
- 60 institutional investors held Harvard Bioscience (HBIO) as of Q3 2025, down from 69 in Q2 2025.
- Funds reported $7.29M of Harvard Bioscience stock for Q3 2025, down 13% quarter-over-quarter.
- 5 funds opened new Harvard Bioscience positions in Q3 2025 and 14 closed out, a net change of -9 holders.
- The largest Harvard Bioscience buyer in Q3 2025 was AMH Equity, an estimated $256K added.
- The largest Harvard Bioscience seller in Q3 2025 was Granahan Investment Management, an estimated $426K sold.
Based on aggregated 13F filings for Q3 2025.